StockData
Trevi Therapeutics, Inc. logo

Trevi Therapeutics, Inc. (TRVI) stock

TRVINasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30
$13.51+0.22 (+1.66%)

Close on Nov 17, 2026Market cap $1.92BP/E –Yield –

Trevi Therapeutics total assets

Total assets on the balance sheet at the end of each period.

Trevi Therapeutics's total assets was $330.52M at Jun 30, 2026. For fiscal 2025 it was $193.44M, up 74.4% from the year before. The highest annual figure on record is $193.44M in fiscal 2025.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$193.44M+74.4%
FY2024Dec 31, 2024$110.90M+24.0%
FY2023Dec 31, 2023$89.40M-27.3%
FY2022Dec 31, 2022$123.02M+219.7%
FY2021Dec 31, 2021$38.48M-18.4%
FY2020Dec 31, 2020$47.13M-21.4%
FY2019Dec 31, 2019$60.00M+470.0%
FY2018Dec 31, 2018$10.53M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$330.52M+58.6%
Q1 FY2026Mar 31, 2026$179.61M+67.8%
Q4 FY2025Dec 31, 2025$193.44M+74.4%
Q3 FY2025Sep 30, 2025$199.36M+189.3%
Q2 FY2025Jun 30, 2025$208.34M+182.3%
Q1 FY2025Mar 31, 2025$107.00M+36.2%
Q4 FY2024Dec 31, 2024$110.90M+24.0%
Q3 FY2024Sep 30, 2024$68.91M-28.1%
Q2 FY2024Jun 30, 2024$73.81M-26.9%
Q1 FY2024Mar 31, 2024$78.56M-32.4%
Q4 FY2023Dec 31, 2023$89.40M-27.3%
Q3 FY2023Sep 30, 2023$95.90M-25.3%
Q2 FY2023Jun 30, 2023$100.98M+24.0%
Q1 FY2023Mar 31, 2023$116.21M+282.4%
Q4 FY2022Dec 31, 2022$123.02M+219.7%
Q3 FY2022Sep 30, 2022$128.36M+306.3%
Q2 FY2022Jun 30, 2022$81.41M+108.0%
Q1 FY2022Mar 31, 2022$30.39M-29.1%
Q4 FY2021Dec 31, 2021$38.48M-18.4%
Q3 FY2021Sep 30, 2021$31.60M-43.5%
Q2 FY2021Jun 30, 2021$39.15M-16.7%
Q1 FY2021Mar 31, 2021$42.86M-21.0%
Q4 FY2020Dec 31, 2020$47.13M-21.4%
Q3 FY2020Sep 30, 2020$55.88M-15.4%
Q2 FY2020Jun 30, 2020$47.01M-37.4%
Q1 FY2020Mar 31, 2020$54.24M+215.6%
Q4 FY2019Dec 31, 2019$60.00M+470.0%
Q3 FY2019Sep 30, 2019$66.02M–
Q2 FY2019Jun 30, 2019$75.12M–
Q1 FY2019Mar 31, 2019$17.19M–
Q4 FY2018Dec 31, 2018$10.53M–

More Trevi Therapeutics figures

See a number that looks wrong?